[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355220-105":59,"doc-detail-355220-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-co-mutations-and-genetic-variations-on-malignancy-risk-in-ras-positive-indeterminate-thyroid-nodules-an-institutional-experience","Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules - an Institutional Experience","","Mutations in RAS proto-oncogenes (NRAS, HRAS, KRAS) are common in thyroid nodules, yet their prognostic value is uncertain. This retrospective analysis evaluated 354 nodules from 346 patients (2018–2023) to assess isolated RAS mutations versus RAS with co-occurring genetic alterations. Isolated RAS occurred in 41.0%, whereas 54.8% showed additional molecular changes. Co-occurring alterations increased malignancy risk and were linked to more aggressive tumor phenotypes, while isolated RAS predominated in indolent neoplasms. Comprehensive molecular profiling supports accurate risk stratification and management.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-co-mutations-and-genetic-variations-on-malignancy-risk-in-ras-positive-indeterminate-thyroid-nodules-an-institutional-experience/355220/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-co-mutations-and-genetic-variations-on-malignancy-risk-in-ras-positive-indeterminate-thyroid-nodules-an-institutional-experience/355220.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient and nodule data were analyzed in this study?","Question",{"text":112,"@type":113},"The study retrospectively analyzed 354 thyroid nodules from 346 patients, with cases from 2018 to 2023, and evaluated cytologic and surgical pathology follow-up when available.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How often did nodules show isolated RAS mutations versus RAS with additional alterations?",{"text":117,"@type":113},"Isolated RAS mutations were found in 41.0% (n=145) of nodules, while 54.8% (n=194) had RAS with additional molecular alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"How did co-occurring genetic alterations affect malignancy risk and tumor behavior compared with isolated RAS?",{"text":121,"@type":113},"Co-occurring alterations markedly increased malignancy risk versus isolated RAS mutations (p=0.0026) and were associated with more aggressive tumor phenotypes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355220,1790193570,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Endocrine Pathology (2026) 37:13  \n[https://doi.org/10.1007/s12022-026-09910-6](https://doi.org/10.1007/s12022-026-09910-6)  \nRESEARCH  \nImpact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience  \nLawrence Q. Wong1 · Zubair W. Baloch1  \nReceived: 10 December 2025 / Accepted: 16 February 2026 © The Author(s) 2026  \nAbstract  \nMutations in RAS proto-oncogenes (NRAS, HRAS, KRAS) are common in thyroid nodules, though their prognostic significance remains unclear. This retrospective study analyzed 354 thyroid nodules from 346 patients (2018–2023) to investigate the clinical and pathological implications of isolated RAS mutations and RAS with co-occurring genetic alterations. Isolated RAS mutations were found in 41.0%(n = 145), while 54.8%(n = 194) had RAS with additional molecular alterations; NRAS was the most frequent subtype (62.1%). Among co-occurring mutations, EIF1AX (46.7%) and TERT (26.7%) were the most common, primarily in NRAS-positive cases. Surgical follow-up data from 302 cases revealed a malignancy rate of 52.3%(n = 158), with 60.1%(n = 95) being invasive encapsulated follicular variant of papillary thyroid carcinoma (IEFVPTC) . NRAS mutations appeared in 64.6% of malignant cases. Isolated RAS mutations were mainly associated with benign/low-risk neoplasms (47.0%), notably follicular adenomas and encapsulated non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), or malignancies (41.0%) . The malignancy rate was higher in nodules with a RAS mutation plus one concomitant molecular alteration (54.3%), and nearly 100% in those with three additional genetic alterations. Co-occurring genetic alterations with RAS mutations markedly increased the risk of malignancy compared with isolated RAS mutations (Fisher’s exact test, two-tailed p= 0.0026) and were associated with more aggressive tumor phenotypes, whereas isolated RAS mutations were more common in indolent neoplasms. Comprehensive molecular profiling is essential for accurate risk stratification and management of indeterminate thyroid nodules.  \nKeywords Thyroid nodule · RAS mutation · NRAS/HRAS/KRAS · Indeterminate cytology · Follicular-patterned lesions · NIFTP · IEFVPTC · Next-generation sequencing  \nIntroduction  \nThyroid cancer is the most common endocrine malignancy, with about 44,020 new cases annually in the U.S. alone [1] . Fine-needle aspiration (FNA) biopsy is essential for evaluating thyroid nodules, offering a minimally invasive method  \n􀀍 Zubair W. Baloch [baloch@pennmedicine.upenn.edu](baloch@pennmedicine.upenn.edu)  \n[Lawrence Q. Wong](Lawrence Q. Wong)  \n[lawrence.wong@pennmedicine.upenn.edu](lawrence.wong@pennmedicine.upenn.edu)  \n1 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 6 Founders Pavilion, 3400 Spruce Street, Philadelphia,  \nPA 19104, USA  \nto assess malignancy risk. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was developed to standardize cytologic interpretation, ensuring consistent and clear communication across institutions [2] . While most nodules are clearly benign or malignant, some fall into indeterminate categories (e.g., atypia of undetermined significance (AUS), follicular neoplasm (FN), or suspicious for malignancy (SM)), where the cytologic results are inconclusive [3, 4] . These cases often lead to unnecessary surgeries, increased patient anxiety, and delayed treatment. To address this, next-generation sequencing (NGS) and molecular analysis are increasingly used to differentiate benign from malignant nodules [5] . ThyroSeq® Genomic Classifier (GC) uses NGS to analyze 112 thyroid-related genes for mutations, fusions, copy number alterations, and gene expression changes linked to thyroid cancer [6] . ThyroSeq® provides  \n1 3  \na personalized report that categorizes the nodule as either positive or negative for malignancy, detailing any gene","cbCaimfqW3Kw1xOP","https://ap.wps.com/l/cbCaimfqW3Kw1xOP","pdf",1076322,"English","# Abstract\n# Keywords\n# Introduction\n# Materials and methods","[{\"question\":\"What patient and nodule data were analyzed in this study?\",\"answer\":\"The study retrospectively analyzed 354 thyroid nodules from 346 patients, with cases from 2018 to 2023, and evaluated cytologic and surgical pathology follow-up when available.\"},{\"question\":\"How often did nodules show isolated RAS mutations versus RAS with additional alterations?\",\"answer\":\"Isolated RAS mutations were found in 41.0% (n=145) of nodules, while 54.8% (n=194) had RAS with additional molecular alterations.\"},{\"question\":\"How did co-occurring genetic alterations affect malignancy risk and tumor behavior compared with isolated RAS?\",\"answer\":\"Co-occurring alterations markedly increased malignancy risk versus isolated RAS mutations (p=0.0026) and were associated with more aggressive tumor phenotypes.\"}]","Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules - an Institutional Experience | PDF",1790116821,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f3b4170481185ae502edea060865f8a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c70a66b701a27e1ded6c219a3f1b2a5.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/485c38531eaf9b9b4b3bd7eee941f69f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d922649aac48c54fbc2075ad5cc7c38.webp",980,1301]